Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Failure of pentagastrin-stimulated calcitonin testing in early manifestation of familial medullary thyroid cancer.

Pirich C, Rendl G, Hauser-Kronberger C, Häusler I.

Wien Klin Wochenschr. 2012 Oct;124(19-20):723-4. doi: 10.1007/s00508-012-0241-y. Epub 2012 Sep 11.

PMID:
22965292
2.

Is basal ultrasensitive measurement of calcitonin capable of substituting for the pentagastrin-stimulation test?

Pina G, Dubois S, Murat A, Berger N, Niccoli P, Peix JL, Cohen R, Guillausseau C, Charrie A, Chabre O, Cornu C, Borson-Chazot F, Rohmer V; Groupe des Tumeurs Endocrines.

Clin Endocrinol (Oxf). 2013 Mar;78(3):358-64. doi: 10.1111/cen.12001.

PMID:
22913268
3.

The identification of false positive responses to the pentagastrin stimulation test in RET mutation negative members of MEN 2A families.

Marsh DJ, McDowall D, Hyland VJ, Andrew SD, Schnitzler M, Gaskin EL, Nevell DF, Diamond T, Delbridge L, Clifton-Bligh P, Robinson BG.

Clin Endocrinol (Oxf). 1996 Feb;44(2):213-20.

PMID:
8849577
4.

The abnormal pentagastrin test.

Gagel RF.

Clin Endocrinol (Oxf). 1996 Feb;44(2):221-2. No abstract available.

PMID:
8849578
5.

Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma.

Kinlaw WB, Scott SM, Maue RA, Memoli VA, Harris RD, Daniels GH, Porter DM, Belloni DR, Spooner ET, Ernesti MM, Noll WW.

Clin Endocrinol (Oxf). 2005 Dec;63(6):676-82.

PMID:
16343103
6.

Timing and extent of thyroid surgery for gene carriers of hereditary C cell disease--a consensus statement of the European Society of Endocrine Surgeons (ESES).

Niederle B, Sebag F, Brauckhoff M.

Langenbecks Arch Surg. 2014 Feb;399(2):185-97. doi: 10.1007/s00423-013-1139-5. Epub 2013 Dec 3.

PMID:
24297502
7.

Prophylactic thyroidectomy in ethnic Chinese patients with multiple endocrine neoplasia type 2A syndrome after the introduction of genetic testing.

Lau GS, Lang BH, Lo CY, Tso A, Garcia-Barcelo MM, Tam PK, Lam KS.

Hong Kong Med J. 2009 Oct;15(5):326-31.

8.

Current understanding and management of medullary thyroid cancer.

Roy M, Chen H, Sippel RS.

Oncologist. 2013;18(10):1093-100. doi: 10.1634/theoncologist.2013-0053. Epub 2013 Sep 13. Review.

9.

RET gene mutations (genotype and phenotype) of multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.

Krampitz GW, Norton JA.

Cancer. 2014 Jul 1;120(13):1920-31. doi: 10.1002/cncr.28661. Epub 2014 Apr 3. Review.

10.

Sporadic hypercalcitoninemia: clinical and therapeutic consequences.

Scheuba C, Kaserer K, Moritz A, Drosten R, Vierhapper H, Bieglmayer C, Haas OA, Niederle B.

Endocr Relat Cancer. 2009 Mar;16(1):243-53. doi: 10.1677/ERC-08-0059. Epub 2008 Nov 5.

11.

Prophylactic thyroidectomy for MEN 2-related medullary thyroid carcinoma based on predictive testing for RET proto-oncogene mutation and basal serum calcitonin in China.

Qi XP, Zhao JQ, Du ZF, Yang RR, Ma JM, Fei J, Cheng J, Han JS, Jin HY, Chen ZG, Wang JQ, Yang YP, Ying RB, Chen XL, Liu WT, Zhao Y, Jiang HL, Zhang XN.

Eur J Surg Oncol. 2013 Sep;39(9):1007-12. doi: 10.1016/j.ejso.2013.06.015. Epub 2013 Jul 9.

PMID:
23849459
12.

Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update.

Wells SA Jr, Pacini F, Robinson BG, Santoro M.

J Clin Endocrinol Metab. 2013 Aug;98(8):3149-64. doi: 10.1210/jc.2013-1204. Epub 2013 Jun 6. Review.

14.

Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.

Sanso GE, Domene HM, Garcia R, Pusiol E, de M, Roque M, Ring A, Perinetti H, Elsner B, Iorcansky S, Barontini M.

Cancer. 2002 Jan 15;94(2):323-30.

15.

Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia type 2A.

Vieira AE, Mello MP, Elias LL, Lau IF, Maciel LM, Moreira AC, Castro M.

Horm Metab Res. 2002 Apr;34(4):202-6.

PMID:
11987030
16.

Results of the calcitonin stimulation test in normal volunteers compared with genetically unaffected members of MEN 2A and familial medullary thyroid carcinoma families.

Wion-Barbot N, Schuffenecker I, Niccoli P, Conte-Devolx B, Lecomte P, Houdent C, Bigorgne JC, Modigliani E.

Ann Endocrinol (Paris). 1997;58(4):302-8.

PMID:
9436479
17.

Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?

Romei C, Tacito A, Molinaro E, Agate L, Bottici V, Viola D, Matrone A, Biagini A, Casella F, Ciampi R, Materazzi G, Miccoli P, Torregrossa L, Ugolini C, Basolo F, Vitti P, Elisei R.

Clin Endocrinol (Oxf). 2015 Jun;82(6):892-9. doi: 10.1111/cen.12686. Epub 2014 Dec 29.

PMID:
25440022
18.

RET mutation p.S891A in a Chinese family with familial medullary thyroid carcinoma and associated cutaneous amyloidosis binding OSMR variant p.G513D.

Qi XP, Zhao JQ, Chen ZG, Cao JL, Du J, Liu NF, Li F, Sheng M, Fu E, Guo J, Jia H, Zhang YM, Ma JM.

Oncotarget. 2015 Oct 20;6(32):33993-4003. doi: 10.18632/oncotarget.4992.

19.

Diagnostic and surgical dilemmas in hereditary medullary thyroid carcinoma.

Allen SM, Bodenner D, Suen JY, Richter GT.

Laryngoscope. 2009 Jul;119(7):1303-11. doi: 10.1002/lary.20299. Review.

PMID:
19444888
20.

Pentagastrin stimulation test and early diagnosis of medullary thyroid carcinoma using an immunoradiometric assay of calcitonin: comparison with genetic screening in hereditary medullary thyroid carcinoma.

Barbot N, Calmettes C, Schuffenecker I, Saint-André JP, Franc B, Rohmer V, Jallet P, Bigorgne JC.

J Clin Endocrinol Metab. 1994 Jan;78(1):114-20.

PMID:
7904611

Supplemental Content

Support Center